AZ Gets IBD Drug Back From Allergan

Rejoins IL-23 Field

Allergan is selling its Crohn’s disease and ulcerative colitis drug brazikumab back to AstraZeneca to satisfy regulators ahead of its link-up with AbbVie, essentially giving the asset to the UK major for free.

Welcome_Home
Brazikumab Back With AstraZeneca • Source: Shutterstock

AstraZeneca PLC is returning to the interleukin-23 space after recovering all the rights to the inflammatory bowel disease drug brazikumab from Allergan PLC which has been divested to avoid antitrust issues ahead of the latter's takeover by AbbVie Inc..

Brazikumab is currently in a Phase IIb/III program in Crohn’s disease and a Phase IIb trial in ulcerative colitis (UC)....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category